Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 16/20 | 0.52 |
| ▸ | ESR1 | P03372 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17210747 | 0.91 | NPC1 (0.42) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL28574546 | 0.91 | NPC1 (0.42) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL14064243 | 0.86 | ESR2 (0.52) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL13628949 | 0.86 | ESR2 (0.52) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL18385879 | 0.86 | NPC1 (0.39) | ESR2CYP3A4CYP2C9CYP2D6KDM1A | |
| SCHEMBL18385877 | 0.86 | NPC1 (0.39) | ESR2CYP3A4CYP2C9CYP2D6KDM1A | |
| SCHEMBL28538282 | 0.84 | HSP90AA1 (0.40) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL28572205 | 0.84 | HSP90AA1 (0.44) | ESR2CYP3A4CYP2C9 | |
| SCHEMBL5099663 | 0.83 | ESR1 (0.62) | ESR2ESR1KIF11ABL1ABCB1 | |
| SCHEMBL12840849 | 0.83 | ESR2 (0.71) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | CCNE2, CCNE1, CCNL2 | ESR2 206/4885ESR1 117/4885CYP3A4 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.